Physician profile
John Lowery Stone
NPI 1740236645
$2,538.88
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $536 · 2021: $389 · 2022: $883 · 2023: $362 · 2024: $17.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $560.81 | 2019-2022 | |
| Dexcom, INC. | $401.05 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $295.09 | 2020-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $200.13 | 2019-2024 | Ubrelvy, Synthroid, Qulipta |
| Corcept Therapeutics | $182.79 | 2020-2022 | |
| Esperion Therapeutics, INC. | $137.08 | 2020 | |
| Amarin Pharma, INC. | $100.38 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.66 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $62.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.91 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.06 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $35.59 | 2019 | |
| Xeris Pharmaceuticals, INC. | $34.62 | 2021 | |
| Shire North American Group INC | $30.69 | 2019 | |
| Grifols USA, LLC | $28.05 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $27.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.45 | 2019-2020 | |
| Welch Allyn | $25.79 | 2021 | |
| Baxter Healthcare | $25.79 | 2022 | |
| Lilly USA, LLC | $25.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.02 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.50 | 2022 | |
| Horizon Therapeutics Plc | $16.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.07 | 2021 | |
| Grt US Holding, INC. | $13.63 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.80 | 2020 | |
| Medtronic Minimed, INC. | $12.71 | 2020 | |
| Recordati_rare_diseases_inc. | $12.22 | 2021 | |
| Eisai INC. | $11.92 | 2020 | |
| Amgen INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.